In January 2018, ES-072 was registered for a phase I clinical trial (CTR20180074) to assess its efficacy in NSCLC patients with EGFR mutations.182 This single-center, open, dose-escalation trial aims to evaluate the safety and tolerability of ES-072 in patients with locally advanced or metastatic NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.